TICKERNERD
Menu
CODXCODXHealthcare · Medical Devices

CODX Stock Forecast: Co-Diagnostics, Inc. Price Predictions for 2026-2027

Last close, 28 Aug 2026
$1.22
−3.17% on the day

The 1 Wall Street analysts covering Co-Diagnostics, Inc. hold a median 12-month price target of $4 — +227.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 28 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.9M
Ticker Nerd rank
36 / 100
Median analyst target
$4.00
Analysts covering
1
Revenue$146K+190.3% y/y
Operating income−$9.2M
Net income−$9.1M
Free cash flow−$8.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.8%
1M
−13.5%
YTD
−75.9%
1Y
−87.9%
From 52W high
−96.8%
From 52W low
+10.9%
$1
$38
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CODX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Co-Diagnostics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Aug 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Accruals
94
Size
93
Revisions
44
Momentum
27
Issuance
16
Quality
9
Value
9
Volatility
6

Growth (99): Sales and profits are climbing, and climbing faster than before.

Volatility (6): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CODX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CODX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15Oct 25Jan 26Apr 26Jul 26CODXHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +227.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Jan 2026Maxim GroupDowngradeHold—
26 Nov 2025Maxim GroupInitiatesBuy—
24 Nov 2025HC Wainwright & Co.ReiteratesNeutral—
28 Oct 2025D. Boral CapitalMaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
19 Sept 2025D. Boral CapitalMaintainsBuy—
17 Sept 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
28 Apr 2025D. Boral CapitalInitiatesBuy—
28 Mar 2025HC Wainwright & Co.MaintainsNeutral—
11 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
12 Aug 2024HC Wainwright & Co.MaintainsNeutral—
17 June 2024HC Wainwright & Co.ReiteratesNeutral—
13 May 2024HC Wainwright & Co.MaintainsNeutral—
15 Mar 2024HC Wainwright & Co.MaintainsNeutral—
29 Dec 2023HC Wainwright & Co.ReiteratesNeutral—
13 Nov 2023HC Wainwright & Co.MaintainsNeutral—
14 Aug 2023HC Wainwright & Co.MaintainsNeutral—
15 May 2023HC Wainwright & Co.ReiteratesNeutral—
20 Mar 2023HC Wainwright & Co.DowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CODX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CODX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Aug 2026, Co-Diagnostics, Inc. returned −87.9% against +19.9% for the S&P 500, dividends included.

CODX vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Oct 25Jan 26Apr 26Jul 26CODXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CODX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Co-Diagnostics, Inc. (CODX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
12.2×

Cheaper than 13% of US stocks

Price / book
0.5×

Cheaper than 86% of US stocks

EV / EBITDA
−0.2×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
2.0%

Higher than 32% of US stocks

Earnings growth (YoY)
190.3%

Higher than 90% of US stocks

Gross margin
−32.8%

Higher than 3% of US stocks

Operating margin
−3732.5%

Higher than 3% of US stocks

Net margin
64.3%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−174.8%

Higher than 8% of US stocks

Return on assets
−59.6%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Co-Diagnostics, Inc. (CODX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Co-Diagnostics, Inc. has a market value of $7.9M and an enterprise value of $6.0M.

  • Revenue in the twelve months to 31 Mar 2026: $718K. The latest quarter grew 2.0% year on year.

  • Net income over the same four quarters: −$48.5M, a −6753.7% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$29.0M, after $750K of capital spending.

  • Shares outstanding: 3.6M.

  • Trailing P/E: −0.0×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Co-Diagnostics, Inc. employs 115 people — $6K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 28 Aug 2026

Data provided by Twelve Data

Peers

CODX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
CODXCo-Diagnostics, Inc.$7.9M
36
ICCMIceCure Medical Ltd.$7.9M
38
AIDX20/20 Biolabs, Inc.$7.6M
5
SINTSINTX Technologies, Inc.$9.5M
27
INBSIntelligent Bio Solutions, Inc.$7.1M
9
NVNOenVVeno Medical Corp.$7.0M
33
ADGMAdagio Medical Holdings, Inc.$10.8M
37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Co-Diagnostics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CODX news & analysis

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

PRNewsWire · 18 Aug 2026neutral

Co-Diagnostics announced that its Chief Commercialization Officer Seth Egan participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on August 13 in Salt Lake City, Utah. The 90-minute event discussed innovation in Utah's medical device industry, AI's impact, data interoperability, and commercialization strategies.

Why it matters — A CODX watcher would care because the company's leadership engaged in an industry forum on commercialization trends and innovation, signalling active involvement in the medical device community.

Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 13 Aug 2026neutral

Co-Diagnostics, Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.

Why it matters — Earnings calls provide insight into the company's financial performance and strategic direction, which is directly relevant to CODX shareholders and watchers.

Co-Diagnostics Reports Second Quarter 2026 Financial Results

PRNewsWire · 13 Aug 2026positive

Co-Diagnostics announced its financial results for the second quarter ended June 30, 2026. Business highlights included Saudi regulatory approval for a manufacturing facility and a lease in Sudair Industrial City for planned localized production and MENA commercialization, participation in a European trade mission and ESCMID Global 2026, and presentation of its tuberculosis platform at the Stop TB Partnership Summit.

Why it matters — CODX watchers would care because the quarter reflects concrete progress on manufacturing expansion, global commercialization outreach, and clinical platform visibility that advance the company's integrated Co-Dx PCR strategy.

Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test

PRNewsWire · 6 Aug 2026positive

Co-Diagnostics announced it submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument for point-of-care use. The submission follows the previously announced completion of the clinical and analytical performance studies supporting the test.

Why it matters — This regulatory submission moves Co-Diagnostics' point-of-care respiratory multiplex test a step closer to potential FDA clearance, which could expand its product portfolio into decentralized testing settings.

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

PRNewsWire · 30 July 2026neutral

Co-Diagnostics announced it will release its second quarter 2026 financial results on August 13, 2026, after market close, and will host a conference call and webcast the same day at 4:30 p.m.

Why it matters — The announcement provides the date and time for CODX's quarterly earnings release and investor webcast, which shareholders and analysts will watch for updates on the company's financial performance.

FAQ

Frequently asked questions about CODX stock

What is the CODX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Co-Diagnostics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CODX stock a buy right now?

Of the 1 analysts covering Co-Diagnostics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Co-Diagnostics, Inc. 36 out of 100 across roughly 4,600 US stocks as at 28 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CODX?

As at 28 Aug 2026, Co-Diagnostics, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will CODX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +227.9% from the last close, and Ticker Nerd's factor model ranks Co-Diagnostics, Inc. 36 out of 100 as at 28 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CODX stock forecast for 2030?

No analyst covering Co-Diagnostics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CODX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has CODX stock performed over the past year?

Co-Diagnostics, Inc. returned -87.9% over the 12 months to 28 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Co-Diagnostics, Inc. do?

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets nucleic acid-based testing technologies for infectious disease detection and related applications.

What is the latest news on CODX?

The most recent item we track (PRNewsWire, 18 Aug 2026): "Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event". Co-Diagnostics announced that its Chief Commercialization Officer Seth Egan participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on August 13 in Salt Lake City, Utah. The 90-minute event discussed innovation in Utah's medical device industry, AI's impact, data interoperability, and commercialization strategies.

Company

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and markets nucleic acid-based testing technologies for infectious disease detection and related applications. Co-Diagnostics focuses on PCR-based solutions, including the Co-Dx PCR platform for point-of-care and at-home testing, as well as diagnostic tests for conditions such as COVID-19, influenza, tuberculosis, hepatitis, malaria, dengue, and other pathogens. The company also develops molecular tools for mosquito testing, agricultural pathogen detection, and genetic analysis in plant and animal genomes. Its proprietary Co-Primers technology is designed to support highly specific test development and simplify complex molecular testing workflows. Headquartered in Salt Lake City, Utah, Co-Diagnostics serves healthcare, public health, research, and agricultural markets through its diagnostics products and development platforms.

CEO Mr. Dwight H. Egan · 115 employees · United States · https://co-dx.com